Skip to main content

Reduced Ejection Fraction clinical trials at UCLA

1 in progress, 0 open to eligible people

Showing trials for
  • INL1 in Patients With Heart Failure and Reduced Ejection Fraction

    Sorry, not currently recruiting here

    This is a multicenter, randomized, double-blind, placebo-controlled, dose-response trial in patients with chronic stable Heart Failure (HF) and reduced Left Ventricular Ejection Fraction (LVEF) to evaluate the efficacy and safety of three INL1 doses compared with placebo. Patients will be treated for approximately 12 weeks with one of three INL1 doses: 50 mg, 150 mg, 300 mg, or, placebo capsules, taken twice daily (BID).

    Torrance, California and other locations

Last updated: